Skip to Content

Abbott Laboratories ABT

Morningstar Rating
$120.04 +1.42 (1.20%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Abbott Seeks to Expand Reach of Libre Franchise to New Patient Populations

While the pandemic caused some of Abbott's segments to balloon (diagnostics) and others to fall short (medical devices), conditions have largely normalized and Abbott's prospects will again rely heavily on its ability to consistently introduce innovative products. On margins, the company has made progress over the last 10 years but still lags key rivals on profitability measures despite competing in businesses that are characterized by attractive margins.

Price vs Fair Value

ABT is trading at a 15% premium.
Price
$120.04
Fair Value
$682.00
Uncertainty
Medium
1-Star Price
$511.30
5-Star Price
$22.30
Economic Moat
Wlvxygp
Capital Allocation
Pkzdvdst

Bulls Say, Bears Say

Bulls

Abbott has been investing in structural heart products and recently entered the left atrial appendage closure market.

Bears

Clinical data on drug-eluting stents and alternative therapies have put a crimp in percutaneous coronary procedures, as medical therapy and coronary bypass have gained favor.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ABT is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$118.62
Day Range
$118.17120.28
52-Week Range
$89.67120.45
Bid/Ask
$118.84 / $121.82
Market Cap
$208.29 Bil
Volume/Avg
3.2 Mil / 4.9 Mil

Key Statistics

Price/Earnings (Normalized)
27.04
Price/Sales
5.23
Dividend Yield (Trailing)
1.73%
Dividend Yield (Forward)
1.83%
Total Yield
2.32%

Company Profile

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Large Core
Total Number of Employees
114,000

Competitors

Valuation

Metric
ABT
RHHBY
BSX
Price/Earnings (Normalized)
27.0412.0732.89
Price/Book Value
5.396.015.13
Price/Sales
5.233.156.93
Price/Cash Flow
21.5611.5730.14
Price/Earnings
ABT
RHHBY
BSX

Financial Strength

Metric
ABT
RHHBY
BSX
Quick Ratio
1.160.990.63
Current Ratio
1.641.351.32
Interest Coverage
10.8614.938.41
Quick Ratio
ABT
RHHBY
BSX

Profitability

Metric
ABT
RHHBY
BSX
Return on Assets (Normalized)
10.63%17.03%8.92%
Return on Equity (Normalized)
20.87%53.42%16.33%
Return on Invested Capital (Normalized)
14.81%26.30%11.43%
Return on Assets
ABT
RHHBY
BSX
See how this stock stacks up to its competitors with Morningstar Investor

Medical Devices Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
SYK
Stryker CorpRjdx$135.3 Bil
MDT
Medtronic PLCZfnr$112.9 Bil
BSX
Boston Scientific CorpNypfxzv$98.9 Bil
EW
Edwards Lifesciences CorpGxssky$52.3 Bil
DXCM
DexCom IncChbfn$47.1 Bil
ZBH
Zimmer Biomet Holdings IncDdcmm$25.7 Bil
ALGN
Align Technology IncVxgxdf$23.1 Bil
PHG
Koninklijke Philips NV ADRQytyvr$18.4 Bil
PODD
Insulet CorpFgpcqj$11.7 Bil

Sponsor Center